Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

NCT03732274 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG: TEW-7197

Sponsor

MedPacto, Inc.

Collaborators

[object Object]